These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29429797)

  • 21. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
    Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
    Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
    Yang VK; Cunningham SM; Rush JE; de Laforcade A
    J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):729-36. PubMed ID: 26990131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
    Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of rivaroxaban in real-life treatment of venous thromboembolism: results of the TEV Survey, an Italian epidemiological study].
    Pesavento R; Iori I;
    G Ital Cardiol (Rome); 2017 Mar; 18(3):239-246. PubMed ID: 28398382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergency Department Discharge of Pulmonary Embolus Patients.
    Frank Peacock W; Coleman CI; Diercks DB; Francis S; Kabrhel C; Keay C; Kline JA; Manteuffel J; Wildgoose P; Xiang J; Singer AJ
    Acad Emerg Med; 2018 Sep; 25(9):995-1003. PubMed ID: 29757489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
    Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
    Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
    [No Abstract]   [Full Text] [Related]  

  • 29. UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: Results from the FIRST Registry.
    Speed V; Patel JP; Roberts LN; Patel RK; Arya R;
    Thromb Res; 2021 Jan; 197():16-19. PubMed ID: 33160116
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.
    Bott-Kitslaar DM; Saadiq RA; McBane RD; Loprinzi CL; Ashrani AA; Ransone TR; Wolfgram AA; Berentsen MM; Wysokinski WE
    Am J Med; 2016 Jun; 129(6):615-9. PubMed ID: 26797081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Contemporary approaches to determine the duration of anticoagulant therapy for venous thromboembolism].
    Lobastov KV
    Khirurgiia (Mosk); 2019; (5):94-103. PubMed ID: 31169827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
    Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
    Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital.
    Clapham RE; Speed V; Czuprynska J; Gazes A; Guppy S; Patel RK; Rea C; Vadher B; Arya R; Roberts LN
    Br J Haematol; 2022 Jan; 196(1):e3-e6. PubMed ID: 34355385
    [No Abstract]   [Full Text] [Related]  

  • 34. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban.
    Janion-Sadowska A; Natorska J; Siudut J; Ząbczyk M; Stanisz A; Undas A
    Thromb Haemost; 2017 Aug; 117(9):1739-1749. PubMed ID: 28771277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case-report of two patients with hereditary protein S deficiency treated by rivaroxaban.
    Lou J; Yin L; Ke X; Zhang L; Xu F; Liu Z
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):405-409. PubMed ID: 32815916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.